Ramon Cacabelos
Overview
Explore the profile of Ramon Cacabelos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1654
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Martinez-Iglesias O, Naidoo V, Carrera I, Corzo L, Cacabelos R
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259364
Neurodegenerative disorders (NDDs) are major health issues in Western countries. Despite significant efforts, no effective therapeutics for NDDs exist. Several drugs that target epigenetic mechanisms (epidrugs) have been recently developed...
12.
Martinez-Iglesias O, Naidoo V, Carril J, Seoane S, Cacabelos N, Cacabelos R
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982820
There is a lack of effective diagnostic biomarkers for neurodegenerative disorders (NDDs). Here, we established gene expression profiles for diagnosing Alzheimer's disease (AD), Parkinson's disease (PD), and vascular (VaD)/mixed dementia....
13.
Carrera I, Corzo L, Naidoo V, Martinez-Iglesias O, Cacabelos R
Int J Med Sci
. 2023 Mar;
20(3):292-306.
PMID: 36860672
Obesity is a major health challenge worldwide, with implications for diabetes, hypertension and cardiovascular disease (CVD). Regular consumption of dark-meat fish is linked to a lower incidence of CVD and...
14.
Martinez-Iglesias O, Naidoo V, Corzo L, Pego R, Seoane S, Rodriguez S, et al.
Genes (Basel)
. 2023 Feb;
14(2).
PMID: 36833292
DNA methylation remains an under-recognized diagnostic biomarker for several diseases, including neurodegenerative disorders. In this study, we examined differences in global DNA methylation (5mC) levels in serum samples from patients...
15.
Cacabelos R, Carril J, Corzo L, Pego R, Cacabelos N, Alcaraz M, et al.
Pharmacogenomics
. 2023 Jan;
24(1):27-57.
PMID: 36628952
Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multipurpose treatments. Polypharmaceutical regimens cause drug-drug interactions and adverse drug reactions, potentially...
16.
Guerra J, Naidoo V, Cacabelos R
Front Pharmacol
. 2023 Jan;
13:1010296.
PMID: 36605398
The growing interest in the development of drugs that target the endocannabinoid system has extended to conditions that affect the audiovestibular pathway. The expression of cannabinoid (CB) receptors in that...
17.
Martinez-Iglesias O, Naidoo V, Carrera I, Corzo L, Cacabelos R
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36432638
Alzheimer's disease (AD), the most common cause of dementia, causes irreversible memory loss and cognitive deficits. Current AD drugs do not significantly improve cognitive function or cure the disease. Novel...
18.
Cacabelos R
Life (Basel)
. 2022 Sep;
12(9).
PMID: 36143469
The main health problems in developed countries are cardiovascular diseases (25-30%), cancer (20-25%) and nervous system disorders (10-15%), which globally account for more than 80% of the morbidity and mortality...
19.
Cacabelos R, Naidoo V, Martinez-Iglesias O, Corzo L, Cacabelos N, Pego R, et al.
Methods Mol Biol
. 2022 Sep;
2547:275-387.
PMID: 36068470
Alzheimer's disease (AD) is a priority health problem in developed countries with a high cost to society. Approximately 20% of direct costs are associated with pharmacological treatment. Over 90% of...
20.
Cacabelos R, Naidoo V, Martinez-Iglesias O, Corzo L, Cacabelos N, Pego R, et al.
Life (Basel)
. 2022 Mar;
12(3).
PMID: 35330211
Alzheimer’s disease (AD) is a priority health problem with a high cost to society and a large consumption of medical and social resources. The management of AD patients is complex...